Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:CBIO

Crescent Biopharma 4/29/2026 Earnings Report

Crescent Biopharma logo
$20.74 +0.51 (+2.52%)
Closing price 04:00 PM Eastern
Extended Trading
$20.79 +0.05 (+0.26%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Crescent Biopharma EPS Results

Actual EPS
-$0.70
Consensus EPS
-$0.85
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Crescent Biopharma Revenue Results

Actual Revenue
$1.04 million
Expected Revenue
$0.36 million
Beat/Miss
Beat by +$682.00 thousand
YoY Revenue Growth
N/A

Crescent Biopharma Announcement Details

Quarter
Date
4/29/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Crescent Biopharma's next earnings date is estimated for Thursday, July 30, 2026, based on past reporting schedules.

Conference Call Resources

Crescent Biopharma Earnings Headlines

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology ...
May 21 at 11:49 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/crescent-biopharma-announces-trial-in-progress-presentation-for-ascend-study-of-cr-001-a-pd-1-x-vegf-bispecific-antibody-at-upcoming-american-society-of-clinical-oncology-asco-2026-annual-meeting-1036185624
Crescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027
May 21 at 5:51 PM  |  quiverquant.comQ
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
May 22 at 1:00 AM  |  Porter & Company (Ad)
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
May 21 at 5:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299810/0/en/crescent-biopharma-announces-trial-in-progress-presentation-for-ascend-study-of-cr-001-a-pd-1-x-vegf-bispecific-antibody-at-upcoming-american-society-of-clinical-oncology-asco-2026.html
Crescent Biopharma Inc CBIO
May 20 at 2:34 PM  |  morningstar.comM
Crescent Biopharma (NASDAQ:CBIO) Trading Down 9.9% - Here's Why
May 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30783470
See More Crescent Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crescent Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescent Biopharma and other key companies, straight to your email.

About Crescent Biopharma

Crescent Biopharma (NASDAQ:CBIO) (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis. In parallel, Crescent is advancing an oncolytic adenovirus program engineered to selectively infect and lyse cancer cells, thereby releasing tumor antigens and amplifying systemic immune responses. Additional preclinical assets explore complementary mechanisms to address resistance in solid tumors.

Research and development activities are conducted primarily in the United States, leveraging a proprietary platform that integrates molecular engineering with immuno‐oncology expertise. Crescent collaborates with contract research organizations and academic institutions to optimize candidate selection, advance preclinical studies and prepare for clinical evaluation.

Founded in 2020 and headquartered in Woodland Hills, California, Crescent Biopharma is led by a management team and scientific advisory board with extensive experience in oncology drug discovery, biologics development and clinical operations. The company is focused on progressing its pipeline through IND-enabling studies and early‐phase clinical trials.

View Crescent Biopharma Profile
Earnings Tools